These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 20932171)

  • 41. Evaluation of chemotherapy with benznidazole and nifurtimox in mice infected with Trypanosoma cruzi strains of different types.
    Andrade SG; Magalhães JB; Pontes AL
    Bull World Health Organ; 1985; 63(4):721-6. PubMed ID: 3936634
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Longitudinal study of the persistence of the therapeutic action of nifurtimox and benznidazole in patients with chronic chagas infection].
    Schenone H; Rojas A; Alfaro E; Concha L; Aranda R
    Bol Chil Parasitol; 1981; 36(3-4):59-62. PubMed ID: 6812600
    [No Abstract]   [Full Text] [Related]  

  • 43. Prospective, historically controlled study to evaluate the efficacy and safety of a new paediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas disease one year after treatment (CHICO).
    Altcheh J; Castro L; Dib JC; Grossmann U; Huang E; Moscatelli G; Pinto Rocha JJ; Ramírez TE;
    PLoS Negl Trop Dis; 2021 Jan; 15(1):e0008912. PubMed ID: 33412557
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Current and developing therapeutic agents in the treatment of Chagas disease.
    Apt W
    Drug Des Devel Ther; 2010 Sep; 4():243-53. PubMed ID: 20957215
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serological and parasitological response in chronic Chagas patients 3 years after nifurtimox treatment.
    Jackson Y; Chatelain E; Mauris A; Holst M; Miao Q; Chappuis F; Ndao M
    BMC Infect Dis; 2013 Feb; 13():85. PubMed ID: 23406191
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Characteristics of Patients for Whom Benznidazole Was Released Through the CDC-Sponsored Investigational New Drug Program for Treatment of Chagas Disease - United States, 2011-2018.
    Herwaldt BL; Dougherty CP; Allen CK; Jolly JP; Brown MN; Yu P; Yu Y
    MMWR Morb Mortal Wkly Rep; 2018 Jul; 67(29):803-805. PubMed ID: 30048425
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and Safety of Nifurtimox in Pediatric Patients with Chagas Disease: Results at 4-Year Follow-Up in a Prospective, Historically Controlled Study (CHICO SECURE).
    Altcheh J; Sierra V; Ramirez T; Pinto Rocha JJ; Grossmann U; Huang E; Moscatelli G; Ding O
    Antimicrob Agents Chemother; 2023 Apr; 67(4):e0119322. PubMed ID: 36975790
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Strategies to enhance access to diagnosis and treatment for Chagas disease patients in Latin America.
    Alonso-Padilla J; Cortés-Serra N; Pinazo MJ; Bottazzi ME; Abril M; Barreira F; Sosa-Estani S; Hotez PJ; Gascón J
    Expert Rev Anti Infect Ther; 2019 Mar; 17(3):145-157. PubMed ID: 30712412
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Treatment of Trypanosoma cruzi infection in the indeterminate phase: experience and current guidelines in Argentina].
    Sosa Estani S; Segura EL
    Medicina (B Aires); 1999; 59 Suppl 2():166-70. PubMed ID: 10668259
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Update on nifurtimox for treatment of Chagas disease.
    Thakare R; Dasgupta A; Chopra S
    Drugs Today (Barc); 2021 Apr; 57(4):251-263. PubMed ID: 33851689
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [The chemotherapy of Chagas disease].
    Stoppani AO
    Medicina (B Aires); 1999; 59 Suppl 2():147-65. PubMed ID: 10668258
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Treatment of chronic Chagas' disease with an association of nifurtimox and corticoid].
    Rassi A; Amato Neto V; de Siqueira AF; Ferriolli Filho F; Amato VS; Rassi GG; Rassi Junior A
    Rev Soc Bras Med Trop; 2002; 35(6):547-50. PubMed ID: 12612733
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Limitations of currently available Chagas disease chemotherapy.
    Murcia L; Carrilero B; Segovia M
    Rev Esp Quimioter; 2012 Mar; 25(1):1-3. PubMed ID: 22488534
    [No Abstract]   [Full Text] [Related]  

  • 54. [Evaluation of the efficacy of nifurtimox in chronic human chagasic infection by using xenodiagnosis (author's transl)].
    Cerisola JA; Neves da Silva N; Prata A; Schenone H; Rohwedder R
    Bol Chil Parasitol; 1977; 32(3-4):51-62. PubMed ID: 416834
    [No Abstract]   [Full Text] [Related]  

  • 55. Etiological treatment for infection by Trypanosoma cruzi.
    Amato Neto V
    Mem Inst Oswaldo Cruz; 1999; 94 Suppl 1():337-9. PubMed ID: 10677751
    [No Abstract]   [Full Text] [Related]  

  • 56. Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities.
    Viotti R; Vigliano C; Lococo B; Alvarez MG; Petti M; Bertocchi G; Armenti A
    Expert Rev Anti Infect Ther; 2009 Mar; 7(2):157-63. PubMed ID: 19254164
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Etiological treatment of chronic Chagas disease.
    Cançado JR
    Rev Inst Med Trop Sao Paulo; 2001; 43(3):173-81. PubMed ID: 11452329
    [No Abstract]   [Full Text] [Related]  

  • 58. Perspectives in Chagas disease treatment.
    Oliveira GB; Avezum Á; Cordeiro Mattos AJ
    Glob Heart; 2015 Sep; 10(3):189-92. PubMed ID: 26407515
    [No Abstract]   [Full Text] [Related]  

  • 59. [Treatment of Chagas' disease with nifurtimox during the first months of life].
    Moya PR; Paolasso RD; Blanco S; Lapasset M; Sanmartino C; Basso B; Moretti E; Cura D
    Medicina (B Aires); 1985; 45(5):553-8. PubMed ID: 3939553
    [No Abstract]   [Full Text] [Related]  

  • 60. Long term evaluation of etiological treatment of chagas disease with benznidazole.
    Cancado JR
    Rev Inst Med Trop Sao Paulo; 2002; 44(1):29-37. PubMed ID: 11896410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.